Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag344 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Xiaojun Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, 523059…. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dongguan Social Development Science and Technology, Beijing Kangmeng Charity Foundation Medical Research Development Fund, Clinical and Basic Research Special Program.
Abstract (Originalsprache)
Background
The standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC) is EGFR tyrosine kinase inhibitors. However, concurrent mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma and combination therapies may offer a superior approach. This study explores the efficacy and safety of osimertinib plus anlotinib as first-line treatment for advanced NSCLC with EGFR co-mutations. Materials and Methods This study prospectively enrolled patients with advanced NSCLC harboring EGFR (19Del/21L858R) mutations and ≥1 mutation in TP53, PIK3CA, or RB1, who had not undergone systemic treatment. Kaplan-Meier survival analysis tested the differences among patients with different concurrent mutations. ctDNA test was administered before and after treatment and its correlation with efficacy.
Results
A total of 38 patients were enrolled, with co-mutations in TP53 (76.3%), PIK3CA (26.3%), and RB1 (2.6%). With a median follow-up of 25.6 months, the median progression-free survival (PFS) was 29.0 months (95% CI, 18.6-NR), and 1-year PFS rate was 85% (95% CI, 70.4%-94.5%). Objective response rate was 73.7% (95% CI, 56.9%-86.3%), and disease control rate was 100.0% (95% CI, 90.7%-100.0%). Adverse events of any grade occurred in all patients. Seven (18.4%) patients experienced grade 3 treatment-related adverse events (TRAEs), with no grade 4 TRAEs or treatment-related deaths.
Conclusion
Osimertinib plus anlotinib shows promising efficacy and manageable toxicity as first-line treatment for advanced NSCLC with EGFR co-mutations (ChiCTR2300070023). Clinical trial registration This study was registered in the Chinese Clinical Trial Registry (ChiCTR) under the registration number ChiCTR2300070023 on March 31, 2023 (https://www.chictr.org.cn).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, 523059, China.
- Department of Oncology, Guangzhou University of Chinese Medicine Dongguan Hospital (Dongguan Hospital of Traditional Chinese Medicine), Dongguan, Guangdong, 523059, China.
- Department of Oncology, Dongguan Houjie Hospital, Dongguan, Guangdong, 523960, China.
- Department of Pulmonary and Critical Care Medicine, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, 523320, China.
- Department of Oncology, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510095, China.
ORCID-Profile: Guanming Jiang
Förderung
- Dongguan Social Development Science and Technology
- Beijing Kangmeng Charity Foundation Medical Research Development Fund
- Clinical and Basic Research Special Program
Zitieren
APA
Yang, X., Tan, Q., Chen, S., Xie, J., Zeng, Y., Zheng, R., Tan, Q., Zhang, W., Yu, C., Hong, Z., Yu, X., & Jiang, G. (2026). Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study. The Oncologist. https://doi.org/10.1093/oncolo/oyag344
Vancouver
Yang X, Tan Q, Chen S, Xie J, Zeng Y, Zheng R, et al. Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study. The Oncologist. 2026. doi:10.1093/oncolo/oyag344
BibTeX
@article{Yang2026,
author = {Yang, Xiaojun and Tan, Qinquan and Chen, Shiyuan and Xie, Jieyun and Zeng, Yihong and Zheng, Ruinian and Tan, Qinglin and Zhang, Wan and Yu, Churen and Hong, Ziying and Yu, Xinpei and Jiang, Guanming},
title = {Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag344}
}
EUVIMED